OWC Pharmaceutical Research (OWC Pharmaceutical Research) LT-Debt-to-Total-Asset : 0.01 (As of Sep. 2019)

View and export this data going back to 2008. Start your Free Trial

What is OWC Pharmaceutical Research LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. OWC Pharmaceutical Research's long-term debt to total assests ratio for the quarter that ended in Sep. 2019 was 0.01.

OWC Pharmaceutical Research's long-term debt to total assets ratio increased from Sep. 2018 (0.00) to Sep. 2019 (0.01). It may suggest that OWC Pharmaceutical Research is progressively becoming more dependent on debt to grow their business.

OWC Pharmaceutical Research LT-Debt-to-Total-Asset Historical Data

The historical data trend for OWC Pharmaceutical Research's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OWC Pharmaceutical Research LT-Debt-to-Total-Asset Chart

OWC Pharmaceutical Research Annual Data

Trend

Dec08

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.50

OWC Pharmaceutical Research Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	0.01	0.01	0.01

OWC Pharmaceutical Research LT-Debt-to-Total-Asset Calculation

OWC Pharmaceutical Research's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2018 is calculated as

LT Debt to Total Assets (A: Dec. 2018 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2018 )	/	Total Assets (A: Dec. 2018 )
	=	0	/	3.553
	=

OWC Pharmaceutical Research's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2019 is calculated as

LT Debt to Total Assets (Q: Sep. 2019 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2019 )	/	Total Assets (Q: Sep. 2019 )
	=	0.021	/	1.773
	=

OWC Pharmaceutical Research (OTCPK:OWCP) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

OWC Pharmaceutical Research LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of OWC Pharmaceutical Research's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

OWC Pharmaceutical Research (OWC Pharmaceutical Research) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » OWC Pharmaceutical Research Corp (OTCPK:OWCP) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Ben Gurion Street, Ramat Gan, ISR, 5257334

Website

http://www.owcpharma.com

OWC Pharmaceutical Research Corp is a medical cannabis research and development company. The firm through its subsidiary researches and develops cannabis-based products and treatments specifically designed for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder (PTSD), migraine, sexual function and skin disorders. It also provides consulting services to governmental and private entities to assist them with developing and implementing tailor-made medical cannabis program.

Executives

Asher Zwebner

director, officer: CHIEF FINANCIAL OFFICER

CDOOR CORPORATION, 20 A REHOV SHAREI TORAH BAYIT VEGAN, JERUSALEM L3 96387